Podcasts about co chief investigator

Matthew Pantelis speaks with Dr Stephanie Wescott, Co-Chief Investigator, Faculty of Education, Monash Uni on teaching teachers how to tackle toxic masculinity. Listen live on the FIVEAA Player. Follow us on Facebook, Twitter and Instagram.  See omnystudio.com/listener for privacy information.

In this episode we speak to Professor Chris Butler who is a GP and professor of primary care at the Nuffield Department of Primary Care Health Science at the University of Oxford. He is also Co-Chief Investigator for the PRINCIPLE trial and the PANORAMIC trial. Paper: Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial https://doi.org/10.3399/BJGP.2022.0083 (https://doi.org/10.3399/BJGP.2022.0083) Colchicine has been proposed as treatment for COVID-19 due to its anti-inflammatory properties, but evidence to support its use is inconclusive, and its effect on time to recovery in the community has not been evaluated. The RECOVERY trial found no benefit with colchicine use among people hospitalised with COVID-19, while the COLCORONA trial found some evidence of a 1.1% and 1.4% absolute reduction in hospitalisations/deaths among adults with suspected or confirmed COVID-19 in the community respectively. In this national, platform adaptive randomised controlled trial, we found evidence of no meaningful benefit with colchicine on time to recovery, and because the threshold for futility on time to recovery was met, randomisation to colchicine was stopped before collecting substantial data on hospitalisations and death, leading to imprecise estimates for that outcome. Our findings add to the evidence currently available and suggest that colchicine should not be recommended for treating symptoms of COVID-19.

Most of us were blindsided by the novel virus SarsCov2, but infectious disease experts had been warning about the possibility of a global pandemic for some years. For them it was never a matter of if, but when. What did come as a surprise was the speed of scientific progress to fight Covid 19. The first effective vaccine, from Pfizer/BioNTech, was developed in under 300 days, followed in successive weeks by Moderna and Oxford/AstraZeneca. The results of the UK's RECOVERY trial, which was organised in a matter of weeks, has saved an estimated million lives worldwide by identifying which treatments are effective in treating Covid 19. And regulators around the globe, like Britain's MHRA, are using innovative programmes to get medical products to people faster. During the pandemic, the world witnessed how fast medicine can advance with an abundance of cash and collaboration. Is progress at this speed and cost sustainable? Sandra Kanthal asks if drug development is something which should still take decades, or have we learned how to permanently accelerate the process? Guests: Rod MacKenzie, Chief Development Officer, Pfizer Nuala Murphy, President Clinical Research Services, Icon Professor Sir Martin Landray, Co-Chief Investigator, RECOVERY Trial Nicholas Jackson, Head of Programmes and Technology, CEPI Christian Schneider, Interim Chief Scientific Officer, MHRA Hilda Bastian, Independent Scientist Producer and Presenter Sandra Kanthal Editor Jasper Corbett

This piece is a discussion regarding the SQUEEZE Study: A prospective multi-centre international observational study of postoperative vasopressor use. The website mentioned in this piece is here: https://www.esahq.org/research/clinical-trial-network/planned-trials/squeeze/ Our conversation with Konstantin Balonov is here: https://www.topmedtalk.com/euroanaes2019-konstantin-balonov/ Presented by Desiree Chappell with Monty Mythen and their guest Ben Creagh-Brown, Clinical Academic Intensivist, Director of Research and Development, Royal Surrey County Hospital NHS Foundation Trust and Co-Chief Investigator of the "Squeeze Study".

This piece is the first of TopMedTalk's 'as live' coverage from the 5th Collaborative Clinical Trials in Anaesthesiology Meeting, Prato, Italy. It's your chance to get virtual a place at one of the most influential gatherings of its kind in the world. This piece is a discussion regarding the SQUEEZE Study: A prospective multi-centre international observational study of postoperative vasopressor use. Presented by Desiree Chappell with Monty Mythen and their guest Ben Creagh-Brown, Clinical Academic Intensivist, Director of Research and Development, Royal Surrey County Hospital NHS Foundation Trust and Co-Chief Investigator of the "Squeeze Study".

Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide adoption of short course chemotherapy for tuberculosis. Following the closure of that unit he joined the MRC’s Uganda AIDS Programme which researched the dynamics of the HIV epidemic in a rural African environment. On his return to the UK he became head of the Division Without Portfolio within the newly formed MRC Clinical Trials Unit with responsibility for developing trials in neglected areas. Andrew is Co-Chief Investigator of STREAM, the first randomised controlled-trial of a treatment regimen for multi-drug resistant TB. In the context of treatment guidelines based on ‘very low quality’ evidence, Andrew designed STREAM to generate gold-standard evidence on the safety and efficacy of the promising 9-month short-course regimen previously evaluated only in observational studies. The trial has subsequently been adapted to test a bedaquiline-containing oral regimen.

Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide adoption of short course chemotherapy for tuberculosis. Following the closure of that unit he joined the MRC’s Uganda AIDS Programme which researched the dynamics of the HIV epidemic in a rural African environment. On his return to the UK he became head of the Division Without Portfolio within the newly formed MRC Clinical Trials Unit with responsibility for developing trials in neglected areas. Andrew is Co-Chief Investigator of STREAM, the first randomised controlled-trial of a treatment regimen for multi-drug resistant TB. In the context of treatment guidelines based on ‘very low quality’ evidence, Andrew designed STREAM to generate gold-standard evidence on the safety and efficacy of the promising 9-month short-course regimen previously evaluated only in observational studies. The trial has subsequently been adapted to test a bedaquiline-containing oral regimen.

Before he gave us his experience of modern medical trials Prof. Peter Sandercock sat down with Mark Pentler to talk about the challenges of keeping up with current research, who is at fault for people's misunderstanding of trial results, and what can be done about it. We also delve into Peter's journey into skepticism. Professor Peter Sandercock (Emeritus Professor of Neurology, University of Edinburgh) set up and ran the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute ischaemic stroke. More recently, he is the Co-Chief Investigator of IST-3, the largest-ever trial of ‘clot-busting’ thrombolytic therapy for acute ischaemic stroke with over 3,000 patients recruited. In this talk he will expose the challenges and explore the successes of clinical trials in the modern era and how they can bring us not only new treatments and new answers, but also new questions. http://www.ed.ac.uk/clinical-brain-sciences/people/principal-investigators/prof-peter-sandercock

As part of our effort to reach out to more people in Edinburgh and the surrounding area, we recently partnered with the Royal College of Physicians of Edinburgh for the first of what we hope will be a much-repeated event in the future. Two fantastic skeptical talks for an audience of people who had never really heard of us, and we're able to bring you one of those talks on the podcast this week. The College were incredibly gracious hosts and special mention must go to Iain Milne & Daisy Cunynghame for their efforts in making it possible. Professor Peter Sandercock (Emeritus Professor of Neurology, University of Edinburgh) set up and ran the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute ischaemic stroke. More recently, he is the Co-Chief Investigator of IST-3, the largest-ever trial of ‘clot-busting’ thrombolytic therapy for acute ischaemic stroke with over 3,000 patients recruited. In this talk he will expose the challenges and explore the successes of clinical trials in the modern era and how they can bring us not only new treatments and new answers, but also new questions. http://www.ed.ac.uk/clinical-brain-sciences/people/principal-investigators/prof-peter-sandercock